Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Completed 139Terminated 49Unknown 27Recruiting 18Active not recruiting 14Withdrawn 8Not yet recruiting 4Suspended 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1CNS 1

Conditions

Thyroid Neoplasms 1Meningioma 1Chondrosarcoma 1

Interventions

Specimen Handling 9Magnetic Resonance Spectroscopy 7Biopsy 6Nivolumab 4Capecitabine 4Bevacizumab 4Radiosurgery 3Paclitaxel 3Irinotecan 3Fluorouracil 3Everolimus 3Docetaxel 3Cyclophosphamide 3Cisplatin 3trifluridine tipiracil drug combination 2spartalizumab 2pembrolizumab 2lenvatinib 2decitabine and cedazuridine drug combination 2daratumumab 2Vincristine 2Taxes 2Radiation 2Prednisone 2Pemetrexed 2Oxaliplatin 2Mitoxantrone 2Leucovorin 2Etoposide 2Epirubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Suspended × Everolimus × Clear all
NCT06955169 2026-05-22

MOMENTUM-1

RTOG Foundation, Inc.

Phase 2 Suspended
153 enrolled
CNS

Meningioma

NCT03139747 2021-10-15

UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone

Thomas Jefferson University

Phase 2 Suspended
5 enrolled
Head & Neck

Thyroid Neoplasms

NCT02008019 2017-08-07

CHONRAD

Centre Leon Berard

Phase 2 Suspended
57 enrolled
Sarcoma

Chondrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡